Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor - PubMed (original) (raw)
. 2002 Nov;125(Pt 11):2381-91.
doi: 10.1093/brain/awf252.
Affiliations
- PMID: 12390966
- DOI: 10.1093/brain/awf252
Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor
Tjalf Ziemssen et al. Brain. 2002 Nov.
Abstract
The clinical effects of glatiramer acetate (GA), an approved therapy for multiple sclerosis, are thought to be largely mediated by a T-helper 1 (TH1) to T-helper 2 (TH2) shift of GA-reactive T-lymphocytes. Current theories propose that activated GA-reactive TH2 cells penetrate the CNS, release anti-inflammatory cytokines such as interleukin (IL)-4, IL-5 and IL-10, and thus inhibit neighbouring inflammatory cells by a mechanism termed 'bystander suppression'. We demonstrate that both GA-specific TH2 and TH1 cells produce the neurotrophin brain-derived neurotrophic factor (BDNF). As the signal-transducing receptor for BDNF, the full-length 145 tyrosine kinase receptor (trk) B, is expressed in multiple sclerosis lesions, it is likely that the BDNF secreted by GA-reactive TH2 and TH1 has neurotrophic effects in the multiple sclerosis target tissue. This may be an additional mechanism of action of GA, and may be relevant for therapies with altered peptide ligands in general. To demonstrate that GA-reactive T cells produce BDNF, we selected four GA-specific, long-term T-cell lines (TCLs), which were characterized according to their cytokine profile by intracellular double-fluorescence flow cytometry. Three TCLs (isolated from a normal subject) had the phenotypes TH1, TH1/TH0, and TH0; the fourth, derived from a GA-treated patient, had the phenotype TH2. To demonstrate BDNF production, we used a combination of RT-PCR (reverse transcription-polymerase chain reaction) and two specially designed techniques for BDNF protein detection: one was based on ELISA (enzyme-linked immunosorbent assay) of supernatants from co-cultures of GA-specific TCLs plus GA-pulsed antigen-presenting cells, and the other on the direct intracellular staining of BDNF in individual T cells and flow cytometric analysis. The different assays and different TCLs yielded similar, consistent results. All four GA-specific T-cell lines, representing the major different TH phenotypes, could be stimulated to produce BDNF.
Comment in
- The Janus face of CNS-directed autoimmune response: a therapeutic challenge.
Kappos L, Duda P. Kappos L, et al. Brain. 2002 Nov;125(Pt 11):2379-80. doi: 10.1093/brain/awf241. Brain. 2002. PMID: 12390965 No abstract available.
Similar articles
- Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy.
Ziemssen T, Kümpfel T, Schneider H, Klinkert WE, Neuhaus O, Hohlfeld R. Ziemssen T, et al. J Neurol Sci. 2005 Jun 15;233(1-2):109-12. doi: 10.1016/j.jns.2005.03.010. J Neurol Sci. 2005. PMID: 15869765 - Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype.
Dhib-Jalbut S, Chen M, Said A, Zhan M, Johnson KP, Martin R. Dhib-Jalbut S, et al. J Neuroimmunol. 2003 Jul;140(1-2):163-71. doi: 10.1016/s0165-5728(03)00170-x. J Neuroimmunol. 2003. PMID: 12864985 - Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor.
Chen M, Valenzuela RM, Dhib-Jalbut S. Chen M, et al. J Neurol Sci. 2003 Nov 15;215(1-2):37-44. doi: 10.1016/s0022-510x(03)00177-1. J Neurol Sci. 2003. PMID: 14568126 - Glatiramer acetate: mechanisms of action in multiple sclerosis.
Ziemssen T, Schrempf W. Ziemssen T, et al. Int Rev Neurobiol. 2007;79:537-70. doi: 10.1016/S0074-7742(07)79024-4. Int Rev Neurobiol. 2007. PMID: 17531858 Review. - Glatiramer acetate therapy for multiple sclerosis: a review.
Perumal J, Filippi M, Ford C, Johnson K, Lisak R, Metz L, Tselis A, Tullman M, Khan O. Perumal J, et al. Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):1019-29. doi: 10.1517/17425255.2.6.1019. Expert Opin Drug Metab Toxicol. 2006. PMID: 17125414 Review.
Cited by
- The relevance of BDNF for neuroprotection and neuroplasticity in multiple sclerosis.
Maiworm M. Maiworm M. Front Neurol. 2024 Aug 1;15:1385042. doi: 10.3389/fneur.2024.1385042. eCollection 2024. Front Neurol. 2024. PMID: 39148705 Free PMC article. Review. - Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?
Bellanca CM, Augello E, Mariottini A, Bonaventura G, La Cognata V, Di Benedetto G, Cantone AF, Attaguile G, Di Mauro R, Cantarella G, Massacesi L, Bernardini R. Bellanca CM, et al. Curr Neuropharmacol. 2024;22(8):1286-1326. doi: 10.2174/1570159X22666240124114126. Curr Neuropharmacol. 2024. PMID: 38275058 Free PMC article. Review. - Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis.
Sohaei D, Thebault S, Avery LM, Batruch I, Lam B, Xu W, Saadeh RS, Scarisbrick IA, Diamandis EP, Prassas I, Freedman MS. Sohaei D, et al. Clin Proteomics. 2023 Aug 29;20(1):33. doi: 10.1186/s12014-023-09418-9. Clin Proteomics. 2023. PMID: 37644477 Free PMC article. - The Role of BDNF in Multiple Sclerosis Neuroinflammation.
Nociti V, Romozzi M. Nociti V, et al. Int J Mol Sci. 2023 May 8;24(9):8447. doi: 10.3390/ijms24098447. Int J Mol Sci. 2023. PMID: 37176155 Free PMC article. Review. - Rett Syndrome and MECP2 Duplication Syndrome: Disorders of MeCP2 Dosage.
Collins BE, Neul JL. Collins BE, et al. Neuropsychiatr Dis Treat. 2022 Nov 29;18:2813-2835. doi: 10.2147/NDT.S371483. eCollection 2022. Neuropsychiatr Dis Treat. 2022. PMID: 36471747 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials